The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Open accessAbstract
Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever. Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1). Licensed therapeutic or vaccine products are not available to treat filovirus diseases. Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential. Here we show that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Biochemical, reporter-based and primer-extension assays indicate that BCX4430 inhibits viral RNA polymerase function, acting as a non-obligate RNA chain terminator. Post-exposure intramuscular administration of BCX4430 protects against Ebola virus and Marburg virus disease in rodent models. Most importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when administered as late as 48 hours after infection. In addition, BCX4430 exhibits broad-spectrum antiviral activity against numerous viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. This is the first report, to our knowledge, of non-human primate protection from filovirus disease by a synthetic drug-like small molecule. We provide additional pharmacological characterizations supporting the potential development of BCX4430 as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda
Towner, J. S., Sealy, T. K., Khristova, M. L., Albariño, C. G., Conlan, S., Reeder, S. A., Quan, P.-L., Lipkin, W. I., Downing, R., Tappero, J. W., et al. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000212 · Cited by 599
Assessment of the Risk of Ebola Virus Transmission from Bodily Fluids and Fomites
Bausch, D. G., Towner, J. S., Dowell, S. F., Kaducu, F., Lukwiya, M., Sanchez, A., Nichol, S. T., Ksiazek, T. G., & Rollin, P. E. (2007) · The Journal of Infectious Diseases · doi:10.1086/520545 · Cited by 522
A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic Fever
Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., & Huggins, J. (1998) · The Journal of Infectious Diseases · doi:10.1086/515386 · Cited by 492
Mühlberger, E., Weik, M., Volchkov, V. E., Klenk, H.-D., & Becker, S. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.2333-2342.1999 · Cited by 486
Geisbert, T. W., Lee, A. C., Robbins, M., Geisbert, J. B., Honko, A. N., Sood, V., Johnson, J. C., de Jong, S., Tavakoli, I., Judge, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60357-1 · Cited by 463
Basic Clinical and Laboratory Features of Filoviral Hemorrhagic Fever
Kortepeter, M. G., Bausch, D. G., & Bray, M. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir299 · Cited by 328
Marburg-virus disease in Kenya
Smith, D. H., Isaacson, M., Johnson, K. M., Bagshawe, A., Johnson, B. K., Swanapoel, R., Killey, M., Siongok, T., & Koinange Keruga, W. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91871-2 · Cited by 324
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease
Dye, J. M., Herbert, A. S., Kuehne, A. I., Barth, J. F., Muhammad, M. A., Zak, S. E., Ortiz, R. A., Prugar, L. I., & Pratt, W. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200409109 · Cited by 268
Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates
Hevey, M., Negley, D., Pushko, P., Smith, J., & Schmaljohn, A. (1998) · Virology · doi:10.1006/viro.1998.9367 · Cited by 262
Warfield, K. L., Swenson, D. L., Olinger, G. G., Kalina, W. V., Aman, M. J., & Bavari, S. (2007) · The Journal of Infectious Diseases · doi:10.1086/520583 · Cited by 260
Self-citationSmither, S. J., Eastaugh, L. S., Steward, J. A., Nelson, M., Lenk, R. P., & Lever, M. S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.012 · Cited by 228
Advanced antisense therapies for postexposure protection against lethal filovirus infections
Warren, T. K., Warfield, K. L., Wells, J., Swenson, D. L., Donner, K. S., Van Tongeren, S. A., Garza, N. L., Dong, L., Mourich, D. V., Crumley, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2202 · Cited by 203
Self-citationFILOVIRUSES - A COMPENDIUM OF 40 YEARS OF EPIDEMIOLOGICAL, CLINICAL, AND LABORATORY STUDIES
Kuhn, J. H., & Calisher, C. H. (2008) · PubMed · doi:10.13140/2.1.1683.5365 · Cited by 200
Geisbert, T. W., Daddario-DiCaprio, K. M., Geisbert, J. B., Reed, D. S., Feldmann, F., Grolla, A., Ströher, U., Fritz, E. A., Hensley, L. E., Jones, S. M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.082 · Cited by 197
Disease modeling for Ebola and Marburg viruses
Bente, D., Gren, J., Strong, J. E., & Feldmann, H. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.000471 · Cited by 179
Bray, M., Driscoll, J., & Huggins, J. W. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00066-8 · Cited by 158
Replication, Pathogenicity, Shedding, and Transmission of Zaire ebolavirus in Pigs
Kobinger, G., Leung, A., Neufeld, J., Richardson, J. S., Falzarano, D., Smith, G. A., Tierney, K. J., Patel, A. R., & Weingartl, H. M. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir077 · Cited by 139
Filoviruses: A Compendium of 40 Years of Epidemiological, Clinical, and Laboratory Studies
Rollin, P. E. (2009) · Emerging infectious diseases · doi:10.3201/eid1512.091044 · Cited by 131
Development and Characterization of a Mouse Model for Marburg Hemorrhagic Fever
Warfield, K. L., Bradfute, S. B., Wells, J., Lofts, L. L., Cooper, M. T., Alves, D. A., Reed, D. K., Tongeren, S. A. V., Mech, C. A., & Bavari, S. (2009) · Journal of Virology · doi:10.1128/jvi.00126-09 · Cited by 114
Self-citation3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice
Bray, M., Raymond, J. L., Geisbert, T. W., & Baker, R. O. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00018-9 · Cited by 103
Development of a broad-spectrum antiviral with activity against Ebola virus
Aman, M. J., Kinch, M. S., Warfield, K. L., Warren, T. K., Yunus, A. S., Enterlein, S. G., Stavale, E. J., Wang, P., Chang, S., & Tang, Q. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.06.001 · Cited by 92
Self-citationAlves, D. A., Glynn, A. R., Steele, K. E., Lackemeyer, M. G., Garza, N. L., Buck, J., Mech, C. A., & Reed, D. S. (2010) · Veterinary Pathology · doi:10.1177/0300985810378597 · Cited by 92
Self-citationIdentification of an antioxidant small-molecule with broad-spectrum antiviral activity
Panchal, R. G., Reid, S. P., Tran, J. P., Bergeron, A. A., Wells, J., Kota, K. P., Aman, J., & Bavari, S. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.10.011 · Cited by 89
Self-citationAntiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection
Warren, T. K., Warfield, K. L., Wells, J., Enterlein, S. G., Smith, M. A., Ruthel, G. T., Yunus, A. S., Kinch, M. S., Goldblatt, M., Aman, M. J., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01315-09 · Cited by 70
Self-citationFGI-104: a broad-spectrum small molecule inhibitor of viral infection.
Kinch, M. S., Yunus, A. S., Lear-Rooney, C. M., Mao, H., Chen, H., Fesseha, Z., Luo, G. G., Nelson, E. A., Li, L., Huang, Z., et al. (2009) · PubMed · Cited by 49
Lou, H. X., Choi, Y. H., LaVoy, J., et al. (2003) · Virology · doi:10.1016/j.virol.2003.08.038 · Cited by 6
Cited by
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., et al. (2016) · Nature · doi:10.1038/nature17180 · Cited by 1,556
Self-citationAgostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., Smith, E. C., Case, J. B., Feng, J. Y., Jordan, R., et al. (2018) · mBio · doi:10.1128/mbio.00221-18 · Cited by 1,416
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Yin, W., Mao, C., Luan, X., Shen, D.-D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. (2020) · Science · doi:10.1126/science.abc1560 · Cited by 1,219
Metadata
- Authors
- Warren, T. K., Wells, J., Panchal, R. G., Stuthman, K. S., Garza, N. L., Van Tongeren, S. A., Dong, L., Retterer, C. J., Eaton, B. P., Pegoraro, G., Honnold, S., Bantia, S., Kotian, P., Chen, X., Taubenheim, B. R., Welch, L. S., Minning, D. M., Babu, Y. S., Sheridan, W. P., & Bavari, S.
- Venue
- Nature
- Published
- 2014-03-02
- Volume
- 508
- Issue
- 7496
- Pages
- 402-405
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2072202424
- Cited by
- 610
- References
- 27
- FWCI
- 48.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.